登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BMJ，5月22日，Features of 20?133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-24

  • Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

    BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1985 (Published 22 May 2020)

    Abstract

    Objective To characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital.

    Design Prospective observational cohort study with rapid data gathering and near real time analysis.

    Setting 208 acute care hospitals in England, Wales, and Scotland between 6 February and 19 April 2020. A case report form developed by ISARIC and WHO was used to collect clinical data. A minimal follow-up time of two weeks (to 3 May 2020) allowed most patients to complete their hospital admission.

    Participants 20 133 hospital inpatients with covid-19.

  • 原文来源：https://www.bmj.com/content/369/bmj.m1985
70浏览量
原文链接
相关报告

  • 《5月22日_英国多机构联合使用ISARIC WHO临床表征方案对20133名英国COVID-19患者特征的前瞻性观察队列研究》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-25
    • 1.时间：2020年5月22日 2.机构或团队：爱丁堡大学、爱丁堡皇家医院、伯明翰大学、英国国立卫生研究院（NIHR）、利物浦大学、兰开斯特大学医学院、牛津大学、诺丁汉大学、格拉斯哥大学、英国公共卫生部、伦敦帝国理工学院 3.事件概要： 5月22日，《英国医学杂志（BMJ）》发表了来自爱丁堡大学等英国多家机构的研究团队的题为“Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study”的文章。旨在表征在COVID-19疫情的第一波暴发期间因COVID-19入院，并纳入国际严重急性呼吸道和新兴感染协会（ISARIC）世界卫生组织（WHO）英国临床表征协议（CCP-UK）研究的患者的临床特征。 ISARIC WHO CCP-UK是一项对COVID-19住院患者进行的大型前瞻性队列研究。该文章通过对在2020年2月6日至4月19日之间，在英格兰、威尔士和苏格兰的 208家急诊医院的20133名COVID-19住院病历的队列研究，探讨与医院死亡率相关的危险因素。ISARIC和WHO编制的病例报告表用于收集临床数据，主要指标为进入重症监护室的住院率和死亡率。两周的最短随访时间（至2020年5月3日）使大多数患者能够完成入院。 结果显示：COVID-19住院患者的中位年龄为73岁，男性比女性多（男性60％，n = 12068；女性40％，n = 8065）。入院前症状的中位持续时间为4天（四分位间距1-8）。最常见的合并症是慢性心脏病（31％，5469/17702）、单纯性糖尿病（21％，3650/17599）、非哮喘性慢性肺病（18％，3128/17634）和慢性肾脏病（16％，2830/17506），23％（4161/18 525）没有报告严重合并症。总体而言，在报告日期，有41％（8199/20133）的患者出院，有26％（5165/20133）的患者死亡，有34％（6769/20 133）继续接受护理。17％（3001/18183）的患者需要进入高度依赖或重症监护病房。进入重症监护病房的3001人中，在报告日，有28％（826/3001）出院，32％（958/3001）死亡，还有41％（1217/3001）继续接受护理。机械通气的患者中，有17％（276/1658）出院，37％（618/1658）死亡，46％（764/1658）仍在医院中。年龄增高、性别为男性以及合并症（包括慢性心脏病、非哮喘性慢性肺部疾病、慢性肾脏病、肝病和肥胖症）均与更高的住院死亡率相关。 4.附件： 原文链接https://www.bmj.com/content/369/bmj.m1985
    148浏览量
    原文链接

  • 《LANCET，5月28日，COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-29
    • COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lennard Y W Lee, DPhil * Prof Jean Baptiste Cazier, PhD * T Starkey, MSc C D Turnbull, DPhil UK Coronavirus Cancer Monitoring Project Team Rachel Kerr, FRCP † et al. Show all authors Show footnotes Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31173-9 Summary Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. Methods In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission.
    98浏览量
    原文链接